Here is a 400-word summary of the content:

Piramal Pharma (PPL), a part of the Piramal group of companies, has expanded its capacity to manufacture Sevoflurane, a critical component used in inhalation anesthesia. The company has set up additional manufacturing capabilities at its Digwal facility, in addition to its existing capacity at its Bethlehem, Pennsylvania, USA facility. This move aims to increase the company’s ability to tap into inhalation anesthesia opportunities in both the USA and Rest of World (ROW) markets.

Piramal Pharma Limited, in collaboration with BrePco Biopharma Ltd, has received regulatory approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Naeoatricon, a new pediatric-strength dopamine hydrochloride infusion for the treatment of hypotension in neonates, infants, and children. Piramal Critical Care (PCC) has secured commercialization rights for the EU, UK, and Norway, and will manage the product in these regions.

Naeoatricon is an age-appropriate, ready-to-use, sterile solution for infusion of dopamine hydrochloride, available in two concentrations: 1.5mg/mL in a 30 mL vial and 4.5mg/mL in a 50 mL vial. Until now, there has been no approved dopamine hydrochloride formulation specifically indicated for use in neonates, infants, or children, with off-label use being a common practice.

The approval of Naeoatricon aims to address this gap, ensuring accurate dosing, minimizing the risk of under or overdosing, and reducing preparation time in neonatal and pediatric intensive care units (NICU & PICU), thus enabling faster intervention in emergency settings. With this approval, Naeoatricon sets a new standard in pediatric critical care.

The availability of Naeoatricon is a significant development in the field of pediatrics, as it provides a safe and reliable solution for healthcare professionals and parents. It aims to improve patient outcomes and optimize treatment in neonatal and pediatric critical care units, ultimately leading to better health outcomes for the most vulnerable patients.

Piramal Pharma, a multi-faceted pharmaceutical company, is poised to achieve its goal of reaching $2 billion in revenues and becoming one of the top 10 companies in its addressable markets by 2030, according to Chairperson Nandini Piramal. The company has been growing at a rate of 10-15% across its various business verticals over the past few years. In the last nine months of FY25, Piramal Pharma reported a growth of 14% compared to the same period in FY24, with revenues of ₹6,397 crore.

One of the company’s main growth drivers is its contract development and manufacturing (CDMO) business, which accounted for 58% of its revenues in FY24. The CDMO business has seen an 18% growth in the last three quarters and aims to grow to $1.2 billion with an EBITDA margin of 25% by 2030. The company’s CDMO business focuses on differentiated services and on-patent molecules, with a strong pipeline of over 150 projects across multiple phases, including 34% in Phase 3 clinical trials. Piramal expects at least half of these products to become commercial and offer long-term manufacturing opportunities for large pharma and emerging biotechs.

The company’s other business verticals, including complex hospital generics, India consumer healthcare, and a joint venture with Abbvie for ophthalmic products, are also performing well. With its global presence and diversified portfolio, Piramal Pharma is well-positioned to achieve its ambitious goals and solidify its position in the pharmaceutical industry.